Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 6;11(10):1846.
doi: 10.3390/diagnostics11101846.

Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status after Neoadjuvant Chemotherapy in Chinese Women with Breast Cancer

Hongbiao Liu  1 , Hongwei Zhan  1 , Ying Zhang  1 , Gangqiang He  1 , Hui Wang  1 , Qiaoxia Zhang  1 , Lili Zheng  1
Affiliations

Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status after Neoadjuvant Chemotherapy in Chinese Women with Breast Cancer

Hongbiao Liu et al. Diagnostics (Basel). .

Abstract

Background: The present retrospective study was designed to evaluate the relative diagnostic utility of breast-specific gamma imaging (BSGI) and breast magnetic resonance imaging (MRI) as means of evaluating female breast cancer patients in China.

Methods: A total of 229 malignant breast cancer patients underwent ultrasound, mammography, BSGI, and MRI between January 2015 and December 2018 for initial tumor staging. Of these patients, 73 were subsequently treated via definitive breast surgery following neoadjuvant chemotherapy (NAC), of whom 17 exhibited a complete pathologic response (pCR) to NAC.

Results: BSGI and MRI were associated with 76.8% (43/56) and 83.9% (47/56) sensitivity (BSGI vs. MRI, p = 0.341) values, respectively, as a means of detecting residual tumors following NAC, while both these approaches exhibited comparable specificity in this diagnostic context. The specificity of BSGI for detecting residual tumors following NAC was 70.6% (12/17), and that of MRI was 58.8% (10/17) (BSGI vs. MRI, p = 0.473).

Conclusion: These results demonstrate that BSGI is a useful auxiliary approach to evaluating pCR to NAC treatment.

Keywords: breast cancer; breast-specific gamma imaging (BSGI); magnetic resonance imaging (MRI); neoadjuvant chemotherapy (NAC); residual tumor size.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Bland–Altman plots compare maximal residual diameter between BSGI and MRI exhibited following NAC. (A) Before NAC. Dashed line indicates the mean difference between two methods, solid lines indicate the limits of the agreements (1.96 standard deviations of the mean difference). (B) After NAC. Dashed line indicates the mean difference between two methods, solid lines indicate the limits of the agreements (1.96 standard deviations of the mean difference).
Figure 2
Figure 2
Breast scans from a 53-year-old woman. (A) Pathologic findings revealing DCIS (×100), necrotic tumor cells, and interstitial fibrosis (Miller-Payne grade 5, pCR). (B) MRI scans revealed non-mass enhancement in the left breast; efficacy evaluation was PD. (C) BSGI revealed clear evidence of abnormal radiotracer uptake in the left breast (maximum T/N = 1.67). (D) BSGI revealed a significant increase in abnormal 99mTc-sestamibi foci in the left breast, consistent with metabolic disease progression (maximum T/N = 2.41; PD).
See this image and copyright information in PMC

References

    1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C., Abate D., Abbasi N., Abbastabar H., Abd-Allah F., Abdel-Rahman O., Abdelalim A., Abdoli A., Abdollahpour I., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: A Systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5:1749–1768. doi: 10.1001/jamaoncol.2019.2996. - DOI - PMC - PubMed
    1. Labrosse J., Osdoit M., Hamy A.S., Coussy F., Pierga J.Y., Reyal F., Laas E. Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis. PLoS ONE. 2020;15:e0234173. doi: 10.1371/journal.pone.0234173. - DOI - PMC - PubMed
    1. Ejlertsen B. Adjuvant chemotherapy in early breast cancer. Dan. Med. J. 2016;63:B5222. - PubMed
    1. Kaufmann M., Von Minckwitz G., Mamounas E.P., Cameron D., Carey L.A., Cristofanilli M., Denkert C., Eiermann W., Gnant M., Harris J.R., et al. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Ann. Surg. Oncol. 2012;19:1508–1516. doi: 10.1245/s10434-011-2108-2. - DOI - PubMed
    1. Palshof F.K., Lanng C., Kroman N., Benian C., Vejborg I., Bak A., Talman M.L., Balslev E., Tvedskov T.F. Prediction of pathologic complete response in breast cancer patients comparing magnetic resonance imaging with ultrasound in neoadjuvant setting. Ann. Surg. Oncol. 2021 doi: 10.1245/s10434-021-10117-8. - DOI - PubMed

LinkOut - more resources